Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anvumetostat Combinations in MTAP-deleted Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers
NCT06360354Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 1, open-label trial of anvumetostat in pancreatic cancer (PC), gastrointestinal cancer and biliary tract cancer (BTC) (4 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events at 2 years and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
pancreatic cancer (PC)gastrointestinal cancerbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06360354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360354.